4579 — RaQualia Pharma Income Statement
0.000.00%
Last trade - 00:00
- ¥13bn
- ¥9bn
- ¥2bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,703 | 1,107 | 2,776 | 2,918 | 1,901 |
Cost of Revenue | |||||
Gross Profit | 1,440 | 969 | 2,456 | 2,686 | 1,656 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,715 | 1,595 | 2,088 | 2,117 | 2,260 |
Operating Profit | -11.8 | -488 | 688 | 801 | -359 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 27.3 | -528 | 881 | 851 | -294 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5.34 | -607 | 756 | 723 | -324 |
Net Income Before Extraordinary Items | |||||
Net Income | 5.34 | -607 | 756 | 723 | -324 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 5.34 | -607 | 756 | 723 | -324 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.128 | -28.9 | 36.8 | 37.1 | -14.3 |
Dividends per Share |